In 2011, a study by Lon and colleagues aimed to develop a PK/PD/DisP model to assess the impact of etanercept, a biologic drug that acts as a TNFα inhibitor, on RA progression in CIA [64]. This evidence concerns the gene TNF and rheumatoid arthritis.